KR20090130081A - 2상 지질-소포 조성물 및 질내 송달에 의한 자궁경부 이형성증의 치료 방법 - Google Patents

2상 지질-소포 조성물 및 질내 송달에 의한 자궁경부 이형성증의 치료 방법 Download PDF

Info

Publication number
KR20090130081A
KR20090130081A KR1020097022186A KR20097022186A KR20090130081A KR 20090130081 A KR20090130081 A KR 20090130081A KR 1020097022186 A KR1020097022186 A KR 1020097022186A KR 20097022186 A KR20097022186 A KR 20097022186A KR 20090130081 A KR20090130081 A KR 20090130081A
Authority
KR
South Korea
Prior art keywords
composition
alpha
interferon
methionine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097022186A
Other languages
English (en)
Korean (ko)
Inventor
마리안나 폴드버리
프라빈 쿠머
존 엠. 도허티
Original Assignee
헬릭스 바이오파마 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헬릭스 바이오파마 코포레이션 filed Critical 헬릭스 바이오파마 코포레이션
Publication of KR20090130081A publication Critical patent/KR20090130081A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097022186A 2007-03-30 2008-03-27 2상 지질-소포 조성물 및 질내 송달에 의한 자궁경부 이형성증의 치료 방법 Ceased KR20090130081A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90932407P 2007-03-30 2007-03-30
US60/909,324 2007-03-30

Publications (1)

Publication Number Publication Date
KR20090130081A true KR20090130081A (ko) 2009-12-17

Family

ID=39807744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097022186A Ceased KR20090130081A (ko) 2007-03-30 2008-03-27 2상 지질-소포 조성물 및 질내 송달에 의한 자궁경부 이형성증의 치료 방법

Country Status (18)

Country Link
US (3) US8945529B2 (https=)
EP (1) EP2134353B1 (https=)
JP (1) JP5587762B2 (https=)
KR (1) KR20090130081A (https=)
AU (1) AU2008234364B2 (https=)
CA (1) CA2681565C (https=)
CY (1) CY1118794T1 (https=)
DK (1) DK2134353T3 (https=)
ES (1) ES2617063T3 (https=)
HR (1) HRP20170250T1 (https=)
HU (1) HUE033256T2 (https=)
LT (1) LT2134353T (https=)
MX (1) MX2009010405A (https=)
PL (1) PL2134353T3 (https=)
PT (1) PT2134353T (https=)
SI (1) SI2134353T1 (https=)
TW (1) TWI440477B (https=)
WO (1) WO2008119160A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) * 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
WO2018213789A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Modified messenger rna comprising functional rna elements
AU2018273410A1 (en) * 2017-05-26 2020-01-16 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
JP7423521B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
WO2020056147A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
WO2020056239A1 (en) 2018-09-14 2020-03-19 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2021056106A1 (en) 2019-09-23 2021-04-01 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents
US20240207444A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
MX2023011157A (es) 2021-03-24 2024-01-25 Glo Pharma Inc Peptidos y metodos para reducir la pigmentacion de la piel.
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
EP4426263A4 (en) * 2021-11-04 2025-09-17 Glo Pharma Inc METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS
US20260035707A1 (en) 2022-07-26 2026-02-05 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
CA2168260C (en) 1993-07-28 2000-04-11 Marianna Foldvari Biphasic multilamellar lipid vesicles
IN184589B (https=) 1996-10-16 2000-09-09 Alza Corp
US5993852A (en) 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile

Also Published As

Publication number Publication date
JP2010522698A (ja) 2010-07-08
ES2617063T3 (es) 2017-06-15
MX2009010405A (es) 2010-02-03
CY1118794T1 (el) 2017-07-12
US20100196453A1 (en) 2010-08-05
HUE033256T2 (hu) 2017-11-28
TWI440477B (zh) 2014-06-11
EP2134353A1 (en) 2009-12-23
TW200846030A (en) 2008-12-01
AU2008234364B2 (en) 2013-10-17
US8945529B2 (en) 2015-02-03
CA2681565C (en) 2016-10-25
US20130224283A1 (en) 2013-08-29
WO2008119160A1 (en) 2008-10-09
SI2134353T1 (sl) 2017-03-31
EP2134353B1 (en) 2016-11-16
JP5587762B2 (ja) 2014-09-10
EP2134353A4 (en) 2013-08-07
PT2134353T (pt) 2017-02-15
LT2134353T (lt) 2017-03-27
AU2008234364A1 (en) 2008-10-09
PL2134353T3 (pl) 2017-06-30
DK2134353T3 (en) 2017-02-20
US20130216610A1 (en) 2013-08-22
CA2681565A1 (en) 2008-10-09
HRP20170250T1 (hr) 2017-04-07

Similar Documents

Publication Publication Date Title
EP2134353B1 (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
JP4755742B2 (ja) 医薬最終処方物におけるナノディスパージョンの使用
JP5981997B2 (ja) 薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬学的組成物
EP2515865B1 (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
JPH05507685A (ja) リン脂質で被覆した微細結晶である水不溶性薬剤の注射可能な製剤
PT711148E (pt) Vesicula lipidica multilamelar bifasica
US10159646B2 (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8992969B2 (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
Foldvari et al. Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
JPWO1991007973A1 (ja) 脂肪乳剤
WO1991007973A1 (en) Fat emulsion
TWI857961B (zh) 減少關節內類固醇的併發症之方法
HK1135913B (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
HK1135913A (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
JP3074731B2 (ja) 脂肪乳剤
CN121731479A (zh) 七叶皂苷钠或其异构体作为渗透促进剂的应用
JPH04173736A (ja) 乳化剤
JPWO1991007962A1 (ja) 脂肪乳剤
Li Pulmonary insulin absorption enhancement by bile salts and liposomes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000